Matthew W. Emmens

2010

In 2010, Matthew W. Emmens earned a total compensation of $14.9M as Former Chairman, President CEO at Vertex Pharmaceuticals, a 23% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,931,638
Option Awards$8,998,774
Salary$1,129,192
Stock Awards$1,842,727
Other$9,829
Total$14,912,160

Emmens received $9M in option awards, accounting for 60% of the total pay in 2010.

Emmens also received $2.9M in non-equity incentive plan, $1.1M in salary, $1.8M in stock awards and $9.8K in other compensation.

Rankings

In 2010, Matthew W. Emmens' compensation ranked 141st out of 10,439 executives tracked by ExecPay. In other words, Emmens earned more than 98.6% of executives.

ClassificationRankingPercentile
All
141
out of 10,439
99th
Division
Manufacturing
46
out of 3,837
99th
Major group
Chemicals And Allied Products
10
out of 923
99th
Industry group
Drugs
7
out of 682
99th
Industry
Pharmaceutical Preparations
6
out of 480
99th
Source: SEC filing on April 4, 2013.

Emmens' colleagues

We found five more compensation records of executives who worked with Matthew W. Emmens at Vertex Pharmaceuticals in 2010.

2010

Peter Mueller

Vertex Pharmaceuticals

Chief Scientific Officer

2010

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2010

Kenneth Boger

Vertex Pharmaceuticals

Chief Legal Officer

2010

Amit Sachdev

Vertex Pharmaceuticals

Senior Vice President, Corporate Affairs and Public Policy, and Commercial Business Lead, Canada

2010

Nancy Wysenski

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

In-depth

You may also like